1. Home
  2. BCYC

as 12-17-2024 4:00pm EST

$
-
-
.
-
-
+
$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.

Founded: 2009 Country:
United Kingdom
United Kingdom
Employees: N/A City: CAMBRIDGE
Market Cap: 1.7B IPO Year: 2019
Target Price: $36.00 AVG Volume (30 days): 880.7K
Analyst Decision: Buy Number of Analysts: 9
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -3.23 EPS Growth: N/A
52 Week Low/High: $12.17 - $28.67 Next Earning Date: 10-31-2024
Revenue: $36,898,000 Revenue Growth: 48.60%
Revenue Growth (this year): 40.52% Revenue Growth (next year): -17.43%

BCYC Daily Stock ML Predictions

Stock Insider Trading Activity of Bicycle Therapeutics plc (BCYC)

Name Ticker Relationship Date Transaction AVG Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Thompson Travis Alvin BCYC CHIEF ACCOUNTING OFFICER Nov 11 '24 Sell $24.99 6,256 $157,113.55 19,241
Skynner Michael BCYC CHIEF TECHNOLOGY OFFICER Oct 3 '24 Sell $22.26 972 $21,636.72 92,945
Hannay Michael Charles Ferguson BCYC CHIEF PROD & SUPPLY CHAIN OFF Oct 3 '24 Sell $22.26 247 $5,498.22 22,398
Thompson Travis Alvin BCYC CHIEF ACCOUNTING OFFICER Oct 3 '24 Sell $22.26 153 $3,405.78 19,241
Crockett Nigel BCYC CHIEF BUSINESS OFFICER Oct 3 '24 Sell $22.26 972 $21,636.72 45,822
Milnes Alistair BCYC CHIEF OPERATING OFFICER Oct 3 '24 Sell $22.26 972 $21,636.72 70,302
Lee Kevin BCYC CHIEF EXECUTIVE OFFICER Oct 3 '24 Sell $22.26 3,212 $71,499.12 380,864

Share on Social Networks: